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dystrophy in PDAPP transgenic mice
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Neuritic plaques are a defining feature of Alzheimer disease (AD) pathology. These structures are composed
of extracellular accumulations of amyloid-β peptide (Aβ) and other plaque-associated proteins, surrounded by
large, swollen axons and dendrites (dystrophic neurites) and activated glia. Dystrophic neurites are thought to
disrupt neuronal function, but whether this damage is static, dynamic, or reversible is unknown. To address
this, we monitored neuritic plaques in the brains of living PDAPP;Thy-1:YFP transgenic mice, a model that
develops AD-like pathology and also stably expresses yellow fluorescent protein (YFP) in a subset of neurons
in the brain. Using multiphoton microscopy, we observed and monitored amyloid through cranial windows in
PDAPP;Thy-1:YFP double-transgenic mice using the in vivo amyloid-imaging fluorophore methoxy-X04, and
individual YFP-labeled dystrophic neurites by their inherent fluorescence. In vivo studies using this system
suggest that amyloid-associated dystrophic neurites are relatively stable structures in PDAPP;Thy-1:YFP transgenic mice over several days. However, a significant reduction in the number and size of dystrophic neurites
was seen 3 days after Aβ deposits were cleared by anti-Aβ antibody treatment. This analysis suggests that ongoing axonal and dendritic damage is secondary to Aβ and is, in part, rapidly reversible.
Introduction
Alzheimer disease (AD) is a neurodegenerative disorder that
results in memory deficits, changes in personality, and cognitive
decline. It is the leading cause of dementia in the US, affecting
approximately 10% of those over 65 and 50% of those over 85 years
of age. One of the invariant pathological hallmarks of AD is the
presence of neuritic plaques in areas of the brain responsible for
memory and cognition. Neuritic plaques consist predominantly
of extracellular fibrils of amyloid-β peptide (Aβ) and are closely
associated with dystrophic neurites, activated microglia, and reactive astrocytes (1–3). The actual mechanisms that contribute to the
pathogenesis of AD are not known; however, compelling genetic
and biochemical evidence suggests that accumulation of amyloidβ protein plays a central role. Thus, preventing or reversing the
formation of amyloid may be a viable treatment.
The dystrophic neurites that surround amyloid deposits are
markedly swollen, distorted axons and dendrites. In AD, the number of dystrophic neurites has been shown to correlate with the
clinical severity of dementia (4), and neuronal dystrophy is associated with synaptic loss in cortical cultures exposed to fibrillar
Aβ (5). Studies in human AD and in transgenic models suggest
that alterations in dendritic curvature and morphology, including
neuritic dystrophy, that are associated with deposits of fibrillar Aβ
Nonstandard abbreviations used: Aβ, amyloid-β peptide; AD, Alzheimer disease;
CAA, cerebral amyloid angiopathy; YFP, yellow fluorescent protein.
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are likely to profoundly effect neural network function, as ascertained by computer modeling (6, 7). Though neuritic dystrophy
is thought to contribute to cognitive impairment by disrupting
neuronal function, many physiological characteristics of dystrophic neurites in vivo remain largely unknown.
Various studies have shown that different anti-Aβ immunotherapies can reduce the amount of brain Aβ deposits in transgenic
mouse models of AD (8–19). It is not known, however, whether
removal of Aβ would reverse neuritic dystrophy and, if so, how rapidly this would occur. Insight into the stability of amyloid plaques,
diffuse Aβ deposits, and cerebral amyloid angiopathy (CAA) in AD
transgenic mouse models has been obtained by in vivo brain imaging using 2-photon microscopy (10, 11, 20–22). When monitored
over a 5-month period using this technique, dense-cored amyloid
plaques in the brains of living APP transgenic mice were seen to
develop very rapidly and for the most part to remain stable in size
and shape, while a small population of plaques appeared to undergo periods of dynamic growth and shrinkage (21). It was further
shown that topical application of antibodies specific for the Aβ
protein to the brains of APP transgenic mice could promote clearance of diffuse Aβ deposits and amyloid as monitored by 2-photon microscopy over a 3- to 8-day period (10, 11). Attempts have
been made to observe neurite changes associated with amyloid in
vivo using fluorescent dextrans to label neurites in transgenic mice
(23). These studies showed that dense-cored plaques could alter
neurite trajectories and disrupt the neuropil in a relatively large
area surrounding the core, but this type of labeling approach was
not conducive to high-resolution, long-term analysis of neuronal
structures in vivo.
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Figure 1
Neuritic plaques and CAA in a living PDAPP;Thy-1:YFP doubletransgenic mouse. Using multiphoton microscopy, we were able to
observe and monitor amyloid plaques and CAA through cranial windows in PDAPP;Thy-1:YFP double-transgenic mice using the in vivo
amyloid-imaging fluorophore methoxy-X04 (blue). These images
were taken approximately 24 hours after an i.p. injection of methoxyX04. Amyloid-associated YFP-labeled dystrophic neurites, as well
as unaffected axons, dendrites, and dendritic spines, were visualized by their inherent fluorescence (green). (A–C) A low-magnification view of an area within the cerebral cortex of a PDAPP;Thy-1:
YFP double-transgenic mouse, in which prominent neuritic plaques
and CAA can be seen. The arrowhead points to CAA and the arrow
to a neuritic plaque in the brain parenchyma. (D–F) A higher-magnification view of a neuritic plaque found in the same area shown
in A. (A and D) YFP only; (B and E) methoxy-X04–stained amyloid
only; (C) merged image of A and B; (F) merged image of D and E.
Scale bars: A–C, 200 μm; D–F, 20 μm.

To study the dynamics of neurite-amyloid interactions and to
investigate the properties of amyloid toxicity in vivo, we analyzed
neuritic plaques in the brains of living PDAPP;Thy-1:YFP transgenic mice, a transgenic mouse model that develops AD-like pathology and also stably expresses yellow fluorescent protein (YFP) in
a subset of neurons in the brain (24). In PDAPP;Thy-1:YFP doubletransgenic mice, large YFP-labeled dystrophic axons and dendrites
associated with fibrillar deposits of Aβ are easily visualized (24).
In the present study, using multiphoton microscopy, we observed
and monitored amyloid through cranial windows in PDAPP;Thy-1:
YFP double-transgenic mice using the in vivo amyloid-imaging
fluorophore methoxy-X04 (25), and individual YFP-labeled dystrophic neurites adjacent to amyloid were visualized over time by
virtue of their inherent fluorescence. We have used this system to
investigate whether amyloid-associated dystrophic neurites undergo dynamic changes over time and whether rapid clearance of Aβ
has an acute affect on neuritic dystrophy in living PDAPP;Thy-1:
YFP double-transgenic mice.
Results
Using an in vivo imaging system, we monitored amyloid-associated dystrophic neurites in the brains of living PDAPP;Thy-1:YFP
double-transgenic mice using multiphoton microscopy. In the
neocortex, these mice express YFP in layer 5 neuronal cell bodies
and their dendrites that extend to the cortical surface. Through
cranial windows, cerebrovascular and parenchymal amyloid
deposits were observed with systemically injected methoxy-X04,

and YFP-labeled dystrophic neurites were visualized by their inherent fluorescence (Figure 1). Figure 1, D–F, shows a neuritic plaque
with multiple large dystrophic neurites imaged in vivo on the initial day of surgery. The exact location of each neuritic plaque analyzed was mapped by virtue of crude stereotaxic coordinates and
more precisely by their relative positions to cerebral blood vessels
(either affected or unaffected by CAA) and other stable fiduciary
markers in the vicinity of the plaque (Figure 1, A–C). This mapping system enabled us to reproducibly identify the same plaques
in living PDAPP;Thy-1:YFP double-transgenic mice during imaging
sessions that were separated by days to weeks (Figure 2).
Using this system, we first analyzed neuritic pathology in living
double-transgenic mice in the absence of any treatment to determine whether the number or size of amyloid-associated dystrophic neurites changed dynamically over a period of 72 hours. To
monitor potential changes in populations of dystrophic neurites,
image stacks that encompassed neuritic plaques were generated
on the initial day of surgery (day 0), and the same plaques were
imaged again 3 days later (day 3). The total number and total
cross-sectional area of dystrophic neurites within a plaque were

Figure 2
Reimaging of a neuritic plaque in a living PDAPP;Thy-1:YFP doubletransgenic mouse. (A and B) A single neuritic plaque imaged through a
cranial window in a living PDAPP;Thy-1:YFP double-transgenic mouse
with 2-photon microscopy on the initial day of surgery. (C and D) The
same plaque shown in A and B, imaged 3 days after surgery. Multiple
neurites of normal caliber and dystrophic neurites (arrows) were easily
visualized with YFP fluorescence (green). A and C show both methoxyX04–labeled amyloid (blue) and YFP-labeled neurites. B and D are
identical to A and C, respectively, but only show the YFP signal. In the
absence of any treatment, the relative number and size of amyloidassociated dystrophic neurites did not significantly change over a 72hour period. Each panel is a projection of multiple focal planes that
span approximately 20 μm. Scale bar: 20 μm.
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Figure 3
Clearance of Aβ deposits by direct application of anti-Aβ antibody to
the surface of the brain. (A) Aβ immunoreactivity in a coronal section from the brain of a PDAPP;YFP double-transgenic mouse that
received no treatment. The mouse was fitted with a cranial window on
day 0 and sacrificed 7 days later. (B) Aβ immunoreactivity in a coronal
section from the brain of a PDAPP;YFP double-transgenic mouse that
received treatment with an N-terminal–specific anti-Aβ antibody (20
μg of 10D5). The antibody was administered directly to the surface
of the brain, directly under the cranial window, during the surgical
procedure on day 0 and sacrificed 7 days later. In both A and B, the
area of the brain exposed by the cranial window lies between the
arrowheads. (C) A higher magnification of the cortical area exposed
by the cranial window in the untreated brain shown in A. (D) A higher
magnification of the cortical area exposed by the cranial window in
the 10D5-treated brain shown in B. Note the region of reduced Aβ
immunoreactivity within 100–200 μm below the cortical surface in the
treated area. Scale bars: 250 μm.

determined for each time point. A dystrophic neurite was defined
as any enlarged YFP-labeled neurite measuring more than 2.5 μm
in diameter. The total dystrophic-neurite cross-sectional area for
a given plaque represents the sum of the largest cross-sectional
area for each individual dystrophic neurite found within the
plaque. This last measure is influenced by both number and size
of individual dystrophic neurites associated with a plaque. Statistical analysis of image data from 23 neuritic plaques in 10 different PDAPP;YFP mice indicates that dystrophic neurites did not
undergo major changes in number or size over a 72-hour period in
the absence of any treatments (see Figure 5).
We next wanted to determine whether an anti-Aβ antibody that
reduces the amount of diffuse Aβ and amyloid in the brains of
PDAPP transgenic mice would promote the rapid recovery of neuritic dystrophy. In previous studies, N-terminal–specific anti-Aβ
antibodies have been shown to decrease Aβ in a region-specific
manner in the brains of PDAPP transgenic mice over a 7- to 8-day
period when administered to the brain surface (10, 11, 16). Using
one of these anti-Aβ antibodies, 10D5, we also found a reduction in
the amount of Aβ deposits in the brains of PDAPP;Thy-1:YFP transgenic mice in the immediate vicinity of the application of the antibody to the cortical surface after 7 days (Figure 3). We sought to
determine whether application of 10D5 to the cortical surface had
any effect on the large dystrophic neurites surrounding amyloid
deposits compared with application of vehicle alone. Interestingly,
in mice receiving 10D5, there was a rapid morphological recovery
of some dystrophic neurites that could be observed over as short
430
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a period as 3 days (Figure 4). While most of the largest dystrophic
neurites did not appear to change dramatically over this period,
the smaller dystrophic neurites were often more shrunken, and
some were no longer observable. In some instances, a neuritic
swelling that had been present on a normal-appearing dendrite or
axonal segment disappeared (Figure 4). Statistical analysis of 18
plaques from 7 different PDAPP;Thy-1:YFP transgenic mice demonstrated that a significant decrease in both number and total
cross-sectional area of dystrophic neurites occurred after 10D5
treatment (Figure 5). Several PDAPP;Thy-1:YFP transgenic mice
receiving 10D5 treatment were followed out to 1 week; the diminution in neuritic dystrophy persisted, and in some cases the number
of dystrophic neurites appeared to decrease relative to the 3-day
time point (data not shown). Based on these data, it appears that
axonal and dendritic structural damage associated with amyloid
deposits is not permanent and is, at least in part, reversible over a
relatively short time frame. Further, the specificity of the antibody
shows that Aβ itself causes these reversible structural changes.
Because of the rapid change in dystrophic neurites induced by
10D5, we wanted to know whether application of this antibody
resulted in a change in total Aβ immunostaining as well as fibrillar Aβ. Since it was difficult to quantitate fibrillar deposits in vivo
using methoxy-X04 in PDAPP;Thy-1:YFP mice, we administered
10D5 to an additional 4 17- to 18-month-old PDAPP mice and
assessed Aβ and thioflavine-S–positive staining in the cortex ipsiand contralateral to antibody application. There was a significant
decrease in both Aβ-positive and thioflavine-S–positive load in
the cortex ipsilateral to 10D5 application (mean ± SEM; Aβ load:
treated/untreated cortex = 0.51 ± 0.13, P = 0.03; thioflavine-S load:
treated/untreated cortex = 0.62 ± 0.107, P = 0.04).
Discussion
The amyloid hypothesis of AD proposes that the onset and progression of AD pathogenesis is primarily influenced by the accumulation of Aβ in the brain (26). Attention has been given recently
to the possibility of using Aβ-related immunotherapy to affect this
accumulation (27). To test whether an anti-Aβ antibody could
actually influence structural neuronal damage associated with
neuritic pathology, we monitored amyloid-associated dystrophic
neurites in living PDAPP;Thy-1:YFP double-transgenic mice treated

Figure 4
Morphological recovery of amyloid-associated neuritic dystrophy in
a PDAPP;Thy1:YFP double-transgenic mouse after anti-Aβ antibody
(10D5) treatment. The 2 panels show the same population of YFPlabeled neurites, which are associated with a neuritic plaque imaged
on the initial day of surgery (A) and 72 hours later (B). The antibody
was administered directly to the surface of the brain during the cranialwindow surgical procedure on day 0. The arrows in the day 0 image (A)
point to 2 enlarged dystrophic neurites, which are absent in the day 3
image (B). The associated amyloid is not shown. Scale bar: 20 μm.
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Figure 5
Repeated-measures ANOVA on data derived from 23 neuritic plaques
imaged from 10 different untreated PDAPP;YFP transgenic mice and
18 plaques imaged from 7 different 10D5-treated PDAPP;Thy-1:YFP
transgenic mice. All dystrophic neurites were imaged on day 0 and
then reimaged on day 3. A significant treatment × day interaction for
both the mean number [F1,28 = 25.092, P = 0.00003] of dystrophic
neurites (A) and the mean total cross-sectional area [F1,28 = 21.037,
P = 0.00009] of dystrophic neurites (B) was seen. In the absence of
treatment, dystrophic neurites did not undergo significant changes
in regard to number or cross-sectional area over a 72-hour period.
However, a significant decrease in both mean number and mean
cross-sectional area was seen in animals receiving 10D5 treatment.
*P < 0.00005 versus untreated group.

with the anti-Aβ mAb 10D5. In previous studies, 10D5 treatments
were shown to cause a local, rapid decrease in the amount of Aβ
deposits in the brains of APP transgenic mice when administered
to the brain surface (10, 11, 16). Using the combination of YFP
to label neurites and methoxy-X04 (25) to label amyloid, we were
able to efficiently monitor morphologically normal and dystrophic amyloid-associated neurites over time with high resolution
using 2-photon microscopy in vivo.
In this study, we found that the amount of plaque-associated
neuritic dystrophy did not change significantly over a 3-day period
in control animals. This is consistent with observations made in
live brain slices taken from PDAPP;Thy-1:YFP double-transgenic
mice in which dystrophic neurites associated with neuritic plaques
did not exhibit dramatic morphological changes when imaged
over short time periods with fluorescence confocal microscopy
(28). The apparent stability of neuritic dystrophy, in both models, probably reflects the chronic nature of this type of injury that
develops over a period of days to months. Conversely, when animals received the anti-Aβ antibody treatment, a rapid reversal of
amyloid-associated neuritic dystrophy was seen. This result was
striking in that it demonstrates that altering brain Aβ can facilitate an acute response to chronically injured axons and dendrites.
It also suggests that the confirmed presence of uncleared Aβ in the
brain contributes to ongoing structural damage to neurites and is
required for at least some of this damage to persist.
The exact mechanism of the effect elicited by direct application
of 10D5 antibody to the brain surface is unclear, although several
possibilities exist. Recent studies have demonstrated that anti-Aβ
antibody–induced clearance of deposited Aβ appears to facilitate
the correction of abnormal plaque-associated neurite curvatures
in PDAPP transgenic mice (16) and promotes the clearance of
early tau pathology in the hippocampal regions of 3xTg-AD mice
(17), a transgenic model that develops both amyloid plaques and
The Journal of Clinical Investigation

neurofibrillary tangles (29). Oddo et al. (29) showed that anti-Aβ
antibody injections into the hippocampus resulted in decreased
tau staining in the somatodendritic compartment of neurons by
5 days. While their study demonstrated that Aβ clearance could
modify the accumulation of cytoplasmic protein staining for tau,
it did not address whether the anti-Aβ antibodies could elicit a
change in the enlarged, distorted axons and dendrites that surround amyloid plaques (i.e., the structural change we know as neuritic dystrophy). Our study and that of Oddo et al. complement
each other in that both show that Aβ clearance may enable the
recovery of a specific abnormality associated with Aβ deposition.
The pathological changes that we were able to assess as well as the
methods that we used allowed us to evaluate an important aspect
of AD-like pathology that was not amenable to prior investigations. By using multiphoton microscopy and intrinsically labeled
neuronal processes, we were able to detect decreases in the size of
enlarged axonal and dendritic swellings in individual plaques over
time. This effect may be due to clearance and/or neutralization
of deposited Aβ. A recent study using electrophysiological measurements in vivo has shown that the insoluble Aβ aggregates are
associated with a disruption in neocortical synaptic function that
is not seen when only soluble forms are present (30). This supports
not only the idea that rapid improvement in neurite structure can
come from clearing of insoluble Aβ deposits but also the idea that
rapid shrinkage of dystrophic neurites has the potential to rapidly improve neuronal and synaptic function. It is conceivable that
some of the rapid behavioral improvements seen following passive
peripheral administration of anti-Aβ antibodies could occur via
rapid changes in dystrophic neurites (31, 32). It will be important
in future studies to directly assess axonal, dendritic, and synaptic function in conjunction with the improvement in structural
abnormalities induced by anti-Aβ antibodies.
In the time frame in which our analysis was performed, the
amyloid cores of the neuritic plaques as assessed by 2-photon
microscopy were still present, but it was not possible, with this
technique, to quantify whether there was an antibody-induced
decrease in amyloid. To address this, we treated a separate group
of PDAPP mice with 10D5 and found that there was a significant
decrease in both Aβ-immunostained and thioflavine-S–positive
plaques. In a separate group of PDAPP mice, we also assessed
whether application of 10D5 to the cortex affected levels of PBSsoluble Aβ over 3 days. We found that this treatment resulted in no
significant change in PBS-soluble Aβ40 or Aβ42 in the treated versus the untreated cortex (data not shown). Taken together, these
results suggest that antibody-induced decrease in the number and
size of dystrophic neurites is due to an effect on fibrillar Aβ.
The observation that only a limited number of dystrophic areas
seemed to recover may reflect the initial phases of an acute response
to a single antibody treatment that might be enhanced with additional time or antibody doses. Alternatively, it may reflect differences in the state of the neuritic injury. For example, dystrophic
neurites that are larger and more mature may not respond to Aβ
clearance as well as a newly developed dystrophic neurite. Thus,
more of a benefit might be seen in younger animals that are just
beginning to develop pathology. To our knowledge, this study provides the first direct evidence that reducing Aβ in the brain can promote the rapid structural recovery of existing amyloid-associated
neuritic dystrophy in vivo. These data have important implications
regarding Aβ clearance as a therapeutic strategy for AD. Our in vivo
imaging model should prove to be a valuable tool to study the nor-
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mal progression of AD-like pathology in transgenic mice and to
assess a wide range of clinically relevant treatments for AD.
Methods
Animals. PDAPP+/–;Thy-1:YFP+/– double-transgenic mice were generated
as described previously (24, 33, 34). All double-transgenic mice used for
this analysis were 17–18 months of age. All animal procedures used in this
study have been approved by the Institutional Review Board at Washington
University School of Medicine.
Surgical procedures. The cranial-window surgical procedure was performed
as described elsewhere with slight modifications (23, 35). Briefly, animals
were anesthetized with isoflurane (4% induction, 1.5% maintenance)
while being immobilized in a custom-made animal stereotaxic apparatus
equipped with an anesthetic mask. The skin was resected from just posterior to the eyes to the base of the skull, and a hole, approximately 4–6 mm in
diameter, was carved into the skull between bregma and lambda with a fine
drill bit. After drilling, the resulting “bone cap” was carefully removed, and
the dura was removed from the exposed brain region. The exposed brain
region was irrigated, and an 8-mm cover glass was sealed to the skull with
dental cement to cover the hole. Animals receiving antibody treatment had
an anti-Aβ mAb, 10D5 (10 μl of a 2-mg/ml solution in Ca++- and Mg++-free
PBS), applied to the exposed brain surface before placement and sealing of
the cover glass (16, 23). Untreated animals used as controls underwent the
same procedure as antibody-treated animals except that PBS without 10D5
antibody was applied to the brain surface.
In vivo brain imaging using 2-photon microscopy. Twenty-four hours before
imaging, PDAPP;Thy-1:YFP transgenic mice were injected i.p. with 10 mg/kg
methoxy-X04 to specifically label amyloid in the brain (25). Anesthetized
mice with cranial windows were placed on the stage of a 2-photon microscope (LSM 510 META NLO system [Carl Zeiss Inc.] with a Chameleon Ti:
Sapphire laser [Coherent Inc.]) while in our custom stereotaxic device. For
simultaneous imaging of methoxy-X04 and YFP, an excitation wavelength
of 860 nm was used. Fluorescence emission from amyloid-bound methoxyX04 and YFP was collected in the ranges of 435–485 nm and 525–650 nm,
respectively. Higher-resolution imaging of YFP-labeled neurites alone was
done with an excitation wavelength of 920 nm. Low-magnification images
were taken to establish map positions of neuritic plaques relative to the
vasculature and other fiduciary markers within the brain. Individual neuritic plaques were imaged with an Achroplan ×40 infrared water immersion lens (0.8 numerical aperture; Carl Zeiss Inc.) for analysis. Images were
acquired as 512 × 512 arrays of 8-bit pixels in z-series stacks originating
at the cortical surface and proceeding downward with a step size approximately equal to the excitation wavelength being used. Z-stack data were
collected for each plaque analyzed on the day of the cranial-window surgery (day 0) and 72 hours after surgery (day 3).
Data analysis. Image stacks from each imaging session were processed
and analyzed using both AIM (version 3.2; Carl Zeiss Inc.) and Metamorph
1. Sisodia, S.S. 1999. Alzheimer’s disease: perspectives for the new millennium. J. Clin. Invest.
104:1169–1170.
2. Golde, T.E., Eckman, C.B., and Younkin, S.G. 2000.
Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment
of Alzheimer’s disease. Biochim. Biophys. Acta.
1502:172–187.
3. Selkoe, D.J. 2001. Alzheimer’s disease: genes, proteins, and therapy. Physiol. Rev. 81:741–766.
4. McKee, A.C., Kosik, K.S., and Kowall, N.W. 1991.
Neuritic pathology and dementia in Alzheimer’s
disease. Ann. Neurol. 30:156–165.
5. Grace, E.A., Rabiner, C.A., and Busciglio, J. 2002.
Characterization of neuronal dystrophy induced by
fibrillar amyloid beta: implications for Alzheimer’s
432

(version 6.1; Universal Imaging Corp.) software. Three-dimensional reconstruction of neuritic plaques from z-series stacks was made using maximum-intensity projections. The resulting 3D images obtained at different
time points for an individual plaque were rotated in space to obtain the
same orientation for analysis. The total number and total cross-sectional area of dystrophic neurites within a plaque were determined for each
time point. A dystrophic neurite was defined as any enlarged YFP-labeled
neurite measuring more than 2.5 μm in diameter. The total dystrophicneurite cross-sectional area for a given plaque represents the sum of the
largest cross-sectional area for each individual dystrophic neurite found
within the plaque. The number and size of dystrophic neurites associated
with each plaque were compared for the 2 time points.
Statistical analysis. The data were analyzed using STATISTICA 6.0 for Windows (StatSoft Inc.), and levels of P < 0.05 were set for significance. Data
regarding the mean number and mean total cross-sectional area of dystrophic neurites were analyzed with repeated-measures ANOVAs that included 1 within-subjects factor (day 0 vs. day 3) and 1 between-subjects factor
(treatment yes vs. no). P values for comparisons exceeding Bonferroni corrected levels (0.05/2 = 0.025) are signified in Figure 5 by asterisks.
Histological analysis. When in vivo analysis was completed on an animal, it
received a 200-mg/kg i.p. injection of pentobarbital followed by a bilateral
thoracotomy and perfusion of 4% paraformaldehyde in PBS through the left
ventricle. Brains were dissected and postfixed in the same fixative overnight at
4°C, and then incubated in 30% sucrose in PBS overnight. Brains were cut into
50-μm sections using a freezing sliding microtome. Immunohistochemical
localization of Aβ- and thioflavine-positive plaques was performed on sections containing treated and nontreated areas to determine the relative densities of Aβ deposits and amyloid as described previously (24).
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